What is Breast Cancer Therapy Market Scope?
Breast cancer is known worldwide as the most common cancer in women. It is a common misconception that breast cancer is viewed as a disease of the developed world. Breast cancer is a cancerous manifestation of breast tissue and is the most common cancer in women worldwide. There are about a million new cases of breast cancer each year. Breast cancer accounts for about 10% of global cancer. The awareness of the impact on survival rates in the case of early diagnosis has increased significantly. The high incidence rate of breast cancer is now becoming an issue and several drug companies are increasingly investing in breast cancer research. Breast cancer is a tumor found in breast tissue. A lump can usually be seen in the chest it shows symptoms such as changes in shape, a newly turned nipple, or a red or scaly patch of skin and fluid coming off the nipple. The WHO had stated that breast cancer affects around 2.1 million women each year and is the leading cause of malignancy-related deaths. Breast cancer is one of the leading causes of death among Singaporean women. Singapore has one of the highest age-adjusted breast cancer incidences in Asia, with an increasing incidence in women in their fifties. Mammography screening in Singaporean women increases the detection rate of early-stage breast cancer with acceptable recall and needle biopsy rates.
The Breast Cancer Therapy market study is being classified by Type (Targeted Therapy, Hormonal Therapy, Chemotherapy, Radiation Therapy and Immunotherapy), by Application (Hospitals, Ambulatory Surgical Centers, Clinics and Retail Pharmacies) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Breast Cancer Therapy market throughout the predicted period.
Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (United States), Merck & Co. (United States), AstraZeneca (United Kingdom), Novartis AG (Switzerland), Astellas Pharma Inc. (Japan), Eli Lilly and Company (United States), Eisai Co., Ltd. (Japan), AbbVie, Inc. (United States) and Janssen Global Services LLC (United States) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Breast Cancer Therapy market by Type, Application and Region.
On the basis of geography, the market of Breast Cancer Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Pfizer Inc., in the year 2019, had launched product IBRANCE. The studies proved the effectiveness of IBRANCE combination therapy for certain patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) b and for metastatic breast cancer (MBC). These studies were also presented in the European Society for Medical Oncology (ESMO) Congress Barcelona in Spain.
US Food and Drug Administration (FDA), in the year 2019, approved the first treatment for a certain type of mammary carcinoma produced by an inherited genetic mutation. Piqray (alpelisib) is a targeted therapy called a PI3K inhibitor. Itís precisely used for advanced breast cancer patientís postmenopausal women, and men Ė whose tumors have the PIK3CA mutation and hormone receptor are (HR) positive and HER2 negative the drug is meant to be used along with Faslodex (fulvestrant), a hormone therapy already approved by the FDA. Recently U.S Food & Drug Administration has approved CDK4/6 inhibitors like abemaciclib, palbociclib, and it was proved to be beneficial in stage 4 cancer and has become a standard treatment in mammary carcinoma.
Influencing Market Trend
- Short Breast-Feeding Timeframe
- Rising Prevalence of Obesity in Women after Menopause
- Rising Use of Hormone Replacement Therapy (HRT) and Oral Birth Control Pills Resulting In Increased Levels of Oestrogen
- Increasing Breast Cancer Prevalence in the Developed Countries
- Growing Awareness Regarding Breast Cancer
- Increasing Rate of Alcohol Consumption in Women
- Rising Shift towards Adoption of Western Lifestyle
- Growing Exposure to Certain Carcinogens and Endocrine Disruptors
- Advancements in Cancer Biology
- Launch of Several Diagnostic and Screening Programs Worldwide
- Favorable Insurance and Reimbursement Policies
- High Cost of Breast Cancer Therapeutics
- Severe Adverse Effects Associated With the Therapy
- Difficulty in Diagnosis
Key Target Audience
Providers of Breast Cancer Therapy, End-Users, Potential Investors, Market Research Firms and Others
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.